Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)

L. Bartalena, L. Chiovato, P. Vitti

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

Original languageEnglish
Pages (from-to)1105-1114
Number of pages10
JournalJournal of Endocrinological Investigation
Volume39
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Graves Disease
Hyperthyroidism
Antithyroid Agents
Thyroidectomy
Hypothyroidism
Iodine
Therapeutics

Keywords

  • Agranulocytosis
  • Alemtuzumab
  • Childhood
  • Graves’ disease
  • Graves’ orbitopathy
  • Hyperthyroidism
  • Methimazole
  • Pregnancy
  • Propylthiouracil
  • Radioiodine
  • Thionamides
  • Thyroidectomy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Management of hyperthyroidism due to Graves’ disease : frequently asked questions and answers (if any). / Bartalena, L.; Chiovato, L.; Vitti, P.

In: Journal of Endocrinological Investigation, Vol. 39, No. 10, 01.10.2016, p. 1105-1114.

Research output: Contribution to journalReview article

@article{100828b93a2e46b38a2d86c2e18c3980,
title = "Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)",
abstract = "Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.",
keywords = "Agranulocytosis, Alemtuzumab, Childhood, Graves’ disease, Graves’ orbitopathy, Hyperthyroidism, Methimazole, Pregnancy, Propylthiouracil, Radioiodine, Thionamides, Thyroidectomy",
author = "L. Bartalena and L. Chiovato and P. Vitti",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s40618-016-0505-x",
language = "English",
volume = "39",
pages = "1105--1114",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "10",

}

TY - JOUR

T1 - Management of hyperthyroidism due to Graves’ disease

T2 - frequently asked questions and answers (if any)

AU - Bartalena, L.

AU - Chiovato, L.

AU - Vitti, P.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

AB - Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.

KW - Agranulocytosis

KW - Alemtuzumab

KW - Childhood

KW - Graves’ disease

KW - Graves’ orbitopathy

KW - Hyperthyroidism

KW - Methimazole

KW - Pregnancy

KW - Propylthiouracil

KW - Radioiodine

KW - Thionamides

KW - Thyroidectomy

UR - http://www.scopus.com/inward/record.url?scp=84987892018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987892018&partnerID=8YFLogxK

U2 - 10.1007/s40618-016-0505-x

DO - 10.1007/s40618-016-0505-x

M3 - Review article

AN - SCOPUS:84987892018

VL - 39

SP - 1105

EP - 1114

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 10

ER -